Intervention

Latanoprost

ClinicalTrials.gov intervention label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 31 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials31

Recruiting0

Common conditions18

Lead sponsors shown15

Clinical trials

31 shown

A Phase III Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension in ChinaNCT06666855 · 2024-11-28

ACTIVE_NOT_RECRUITING

A Clinical Study to Evaluate the Efficacy and Safety of CKD-351NCT03762369 · 2018-12-07

CATS Tonometer IOP Reduction Latanoprost Verses TimololNCT04178863 · 2018-07-01

Prospective, Single Center Switching Study of 0.0015% Tafluprost Ophthalmic Solution in Primary Open-angle Glaucoma and Ocular Hypertension Patients With Corneal Disorders (Switching From 0.005% Latanoprost Ophthalmic Solution)NCT04737928 · 2018-04-02

A Multi-center, Randomized, Blinded Evaluator, Active Control, Parallel, Phase III Study to Evaluate the Efficacy and Safety of TJO-002 in POAG or Ocular Hypertension PatientsNCT03419975 · 2016-04-26

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO5093151 in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT).NCT02622334 · 2015-12-29

Stop Retinal Ganglion Cell Dysfunction StudyNCT02390284 · 2015-09-01

28-Day Repeated Topical Study to Evaluate the Safety and Activity of 5 Escalating Dose Levels of SAR366234 and One Dose of Latanoprost in Patients With Open Angle Glaucoma or Ocular HypertensionNCT02531152 · 2015-09-01

A 28 Day Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)NCT02083289 · 2014-05-01

Choroidal Thickness and Its Correlations With Ocular Parameters in Primary Open-angle GlaucomaNCT03966560 · 2014-01-01

Blood Flow of Ophthalmic Artery and GlaucomaNCT02656979 · 2013-12-01

A Phase II Study to Evaluate the Additivity of Trabodenoson to Latanoprost in Adults With Ocular Hypertension or Primary Open-Angle GlaucomaNCT01917383 · 2013-08-01

Study to Compare the Safety and Efficacy of ALZ-1101 to Latanoprost in Patients With Intraocular Pressure Inadequately Controlled by LatanoprostNCT01896180 · 2013-07-01

Latanoprost/Brinzolamide BID Versus Latanoprost BID in Patients With OAG or OHNCT01721707 · 2012-12-01

Switching From Preserved to Preserved-free Treatments for Glaucoma.NCT01433900 · 2012-05-01

Clinical Evaluation of Efficacy of SLT to Topical Medication in Lowering IOPNCT01639807 · 2011-10-01

Safety/Efficacy Study: OPA-6566 Ophthalmic Solution in Subjects With Primary Open-Angle Glaucoma or Ocular HypertensionNCT01410188 · 2011-09-01

Effects of Anti-Glaucoma Medications on the Ocular SurfaceNCT01315574 · 2011-02-01

Safety Study of Latanoprost Slow Release InsertNCT01180062 · 2011-01-01

Study Comparing the Safety and Efficacy of BOL-303259-X to Latanoprost in Subjects With Glaucoma or Ocular HypertensionNCT01223378 · 2010-12-13

Safety and Efficacy Study of Catioprost® (Unpreserved Latanoprost 0.005% Emulsion) Compared to Travatan Z® to Treat Glaucoma and Ocular Surface DiseaseNCT01254370 · 2010-11-01

Topical Application of Latanoprost in Diabetic RetinopathyNCT01225653 · 2010-11-01

Efficacy Comparison of Xalatan and Azopt on POAG and OHNCT01084902 · 2010-02-01

Central Corneal Thickness and 24-hour Fluctuation of Intraocular PressureNCT00941525 · 2009-09-01

A Phase 2 Study of Punctal Placement of the Latanoprost Punctal Plug Delivery System (L-PPDS)NCT00821002 · 2009-01-01

Efficacy, Tolerability and Safety of RKI983 (0.05% & 0.10%) vs Xalatan in Patients With POAG or Ocular HypertensionNCT00846989 · 2009-01-01

Circadian Rhythms of Aqueous Humor Dynamics in HumansNCT00572936 · 2006-03-13

Comparison of Latanoprost Vs. TimololNCT00579969 · 2003-12-01

A Study to Assess the Efficacy of 3 Months of Latanoprost Treatment in Reducing the Intraocular Pressure in Patients With Ocular Hypertension or Open-angle GlaucomaNCT00647101 · 2003-12-01

24-hour Control of Intraocular Pressure (IOP) in Ocular HypertensionNCT01655758 · 2002-01-01

A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Open-Angle Glaucoma (OAG) or Ocular Hypertension (OHT)NCT00051142 · 2001-02-01

Common conditions

Ocular Hypertension15 Glaucoma10 Glaucoma, Open-Angle3 Open Angle Glaucoma3 Primary Open-angle Glaucoma3 Ocular Hypertension (OHT)2 Diabetic Retinopathy1 Elevated Intraocular Pressure1 Glaucoma, Primary Open Angle1 Glaucoma; Drugs1 Intraocular Pressure1 Ocular Surface Disease1 Open Angle Glaucoma -Ocular Hypertension1 Open Angle-glaucoma1 Open-Angle Glaucoma1 Primary Open Angle Glaucoma1 Primary Open Angle Glaucoma (POAG)1 Primary Open-Angle Glaucoma (POAG)1

Leading sponsors

University of Nebraska 2 Adapt Produtos Oftalmológicos Ltda. 1 Afyon Kocatepe University Hospital 1 Alcon Research 1 Alleanza Pharmaceuticals, Inc. 1 Aristotle University Of Thessaloniki 1 Aurolab 1 Bausch & Lomb Incorporated 1 Chong Kun Dang Pharmaceutical 1 Daniel Moore 1 Hoffmann-La Roche 1 Inotek Pharmaceuticals Corporation 1 Intuor Technologies, Inc. 1 Kubota Vision Inc. 1 Massachusetts Eye and Ear Infirmary 1

Trial status mix

COMPLETED19

UNKNOWN6

TERMINATED4

ACTIVE_NOT_RECRUITING1

WITHDRAWN1

Phase mix

PHASE210

PHASE37

PHASE47

PHASE15

NA4

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.